Chimerix (CMRX)
(Delayed Data from NSDQ)
$0.87 USD
+0.02 (1.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $0.87 0.00 (0.46%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.87 USD
+0.02 (1.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $0.87 0.00 (0.46%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Zacks News
The Zacks Analyst Blog Highlights: Chimerix, MacroGenics, Rockwell Medical, TG Therapeutics and Valeritas
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chimerix, MacroGenics, Rockwell Medical, TG Therapeutics and Valeritas
5 Beaten-Down Medical Product Stocks to Rebound in 2019
by Nabaparna Bhattacharya
As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.
Chimerix (CMRX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Chimerix (CMRX) delivered earnings and revenue surprises of 21.43% and -61.84%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Chimerix (CMRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Chimerix (CMRX) delivered earnings and revenue surprises of 11.36% and 27.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Chimerix Q4 Loss Narrower Than Expected, Revenues Exceed
by Zacks Equity Research
Chimerix (CMRX) makes progress in Q4 through advancement with lead product candidate, brincidofovir. Revenues decline from lower reimbursable expenses regarding BARDA developmental contract.
Chimerix (CMRX) Q2 Loss Narrower than Expected, Revenues Down
by Zacks Equity Research
Chimerix (CMRX) revenues in Q2 were hurt by reduced reimbursable expenses related to the company's BARDA developmental contract.
Medical Device Stocks to Beat Estimates this Earnings Season
by Zacks Equity Research
Most of the MedTech majors will be releasing earnings later this month.
Universal Health (UHS) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Universal Health Services, Inc. (UHS) will release fourth-quarter 2016 results on Feb 28, after the market closes. Last quarter, the company posted a negative earnings surprise of 4.19%.
5 Breakout Stocks for Superior Returns
by Swarup Gupta
If properly implemented, such a strategy could deliver impressive returns.
Will Chimerix (CMRX) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Chimerix, Inc. (CMRX)
Falling Earnings Estimates Signal Weakness Ahead for Agios Pharmaceuticals (AGIO)
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.